NDAC Chair Gives Vote Of Confidence To Simultaneous Voting
This article was originally published in The Tan Sheet
Executive Summary
FDA's use of "simultaneous voting" at advisory committee meetings concerning OTC issues in December allowed members to vote free of influence by other members' votes while also proceeding with few technical problems
You may also be interested in...
Data Support Phenylephrine Efficacy, But More Studies Needed – NDAC
FDA's Nonprescription Drugs Advisory Committee recommends additional studies on phenylephrine efficacy for treatment of nasal congestion, although members say current data support the efficacy of the OTC cough/cold ingredient
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
FDA advisory committee changes
FDA releases a 1draft guidance on changes to advisory committee processes, according to a notice slated for publication in the Nov. 19 Federal Register. Among changes, advisory committee members would vote simultaneously rather than sequentially on issues before the panel to avoid influencing one another's votes, the agency says. Although FDA does not mandate any particular voting method, it suggests voting by show of hands, a simultaneous show of "yes" or "no" cards or written balloting. Changes are part of ongoing reforms to the agency's advisory committee policies based on recommendations from the Institute of Medicine and pressure from Congress. In March, FDA issued a draft guidance limiting the potentially conflicting financial interests of members (2"The Tan Sheet" March 26, 2007, p. 7)...